← All drugs
Drug · FAERS side-effect profile with label screen

Oxycodone side effects: what 185,825 FDA adverse event reports show

Oxycodone · Oxycodone Hydrochloride · 1,186 reaction terms · 971,310 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Oxycodone Hydrochloride

openFDA label

Who reports

185,825 reports · 82% serious · 53,015 with death outcome · 54% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.

FDA label, Indications and Usage

What it is

Oxycodone is a semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.

PubChem CID 5284603 (ChEBI)

Boxed warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 6Reporting / coding artifact 2Lab value / disease marker 8Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,146 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
C-reactive protein527157.6
138.0–180.0ROR 158.0 · calibrated p 3e-9 ✓
65.3 EB05 60.8 · IC025 +5.8
3/3 methods agree
Lab value / disease markerserious n=527 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Facet joint syndrome1,653125.0
116.5–134.1ROR 126.1 · calibrated p 2e-8 ✓
59.1 EB05 56.7 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious n=1,653 · ♀ 100% (drug 54%) · 94% clinicianno trial arm names this drug
Deep vein thrombosis postoperative981113.3
103.7–123.9ROR 113.9 · calibrated p 4e-8 ✓
56.4 EB05 53.5 · IC025 +5.7
3/3 methods agree
Not in label — unassessedserious n=981 · ♀ 100% (drug 54%) · 91% clinicianno trial arm names this drug
Duodenal ulcer perforation3,547105.8
101.1–110.8ROR 107.8 · calibrated p 6e-8 ✓
54.5 EB05 53.0 · IC025 +5.7
3/3 methods agree
Not in label — unassessedserious PRR 38.4 · ♀ 100% (drug 54%) · 94% clinicianno trial arm names this drug
Rheumatic fever1,97192.9
87.5–98.6ROR 93.9 · calibrated p 2e-7 ✓
50.9 EB05 49.0 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious n=1,971 · ♀ 100% (drug 54%) · 96% clinicianno trial arm names this drug
Swollen joint count increased1,36387.6
81.6–94.1ROR 88.3 · calibrated p 3e-7 ✓
49.3 EB05 47.1 · IC025 +5.5
3/3 methods agree
Lab value / disease markerserious n=1,363 · ♀ 100% (drug 54%) · 97% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive3,05885.3
81.4–89.4ROR 86.7 · calibrated p 3e-7 ✓
48.5 EB05 47.1 · IC025 +5.5
3/3 methods agree
Lab value / disease markerserious PRR 34.3 · ♀ 100% (drug 54%) · 93% clinicianno trial arm names this drug
Lupus vulgaris48878.4
69.8–88.0ROR 78.6 · calibrated p 7e-7 ✓
46.2 EB05 42.8 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=488 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Folliculitis4,19377.1
74.1–80.2ROR 78.8 · calibrated p 6e-7 ✓
45.8 EB05 44.6 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious PRR 37.9 · ♀ 100% (drug 54%) · 94% clinicianno trial arm names this drug
Red blood cell sedimentation rate11476.7
60.4–97.4ROR 76.7 · calibrated p 1e-6 ✓
45.3 EB05 38.8 · IC025 +4.9
3/3 methods agree
Lab value / disease markerserious n=114 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody26976.1
65.2–88.9ROR 76.2 · calibrated p 9e-7 ✓
45.3 EB05 40.9 · IC025 +5.2
3/3 methods agree
Lab value / disease markerserious n=269 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Adjustment disorder with depressed mood74766.3
60.6–72.6ROR 66.6 · calibrated p 2e-6 ✓
41.8 EB05 39.3 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=744 · ♀ 100% (drug 54%) · 96% clinicianno trial arm names this drug
Swollen joint count9166.1
50.9–85.6ROR 66.1 · calibrated p 3e-6 ✓
41.4 EB05 34.7 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=91 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Hypocholesterolaemia11264.4
51.0–81.2ROR 64.4 · calibrated p 3e-6 ✓
40.8 EB05 34.8 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=112 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Drug diversion2,01361.1
57.8–64.5ROR 61.7 · calibrated p 3e-6 ✓
39.6 EB05 38.2 · IC025 +5.2
3/3 methods agree
Reporting / coding artifactserious n=1,047 · 95% consumerno trial arm names this drug
Helicobacter infection3,54460.0
57.6–62.5ROR 61.1 · calibrated p 4e-6 ✓
39.2 EB05 38.1 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious PRR 29.2 · ♀ 100% (drug 54%) · 94% clinicianno trial arm names this drug
Dislocation of vertebra72554.4
49.8–59.4ROR 54.6 · calibrated p 8e-6 ✓
36.7 EB05 34.5 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=725 · ♀ 100% (drug 54%) · 94% clinicianno trial arm names this drug
X-ray abnormal54649.5
44.8–54.8ROR 49.7 · calibrated p 1e-5 ✓
34.5 EB05 32.1 · IC025 +4.9
3/3 methods agree
Lab value / disease markerserious n=545 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Pemphigus3,67947.2
45.5–49.1ROR 48.2 · calibrated p 2e-5 ✓
33.4 EB05 32.5 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious PRR 23.6 · ♀ 100% (drug 54%) · 94% clinicianno trial arm names this drug
C-reactive protein abnormal1,80143.9
41.6–46.4ROR 44.4 · calibrated p 3e-5 ✓
31.7 EB05 30.5 · IC025 +4.9
3/3 methods agree
Lab value / disease markerserious n=1,801 · ♀ 85% (drug 54%) · 92% clinicianno trial arm names this drug
Rheumatoid factor positive1,57642.2
39.8–44.7ROR 42.6 · calibrated p 4e-5 ✓
30.8 EB05 29.5 · IC025 +4.8
3/3 methods agree
Lab value / disease markerserious n=1,576 · ♀ 100% (drug 54%) · 97% clinicianno trial arm names this drug
Hand deformity3,51241.2
39.7–42.8ROR 42.0 · calibrated p 4e-5 ✓
30.3 EB05 29.4 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious PRR 23.2 · ♀ 100% (drug 54%) · 93% clinicianno trial arm names this drug
Retinitis43439.4
35.4–44.0ROR 39.5 · calibrated p 6e-5 ✓
29.3 EB05 27.0 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=434 · ♀ 100% (drug 54%) · 100% clinicianno trial arm names this drug
Pericarditis3,60030.9
29.8–32.1ROR 31.5 · calibrated p 2e-4 ✓
24.4 EB05 23.7 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious PRR 17.3 · ♀ 100% (drug 54%) · 93% clinicianno trial arm names this drug
Victim of homicide12130.5
25.0–37.4ROR 30.6 · calibrated p 3e-4 ✓
24.1 EB05 20.7 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=121 · ♀ 0% (drug 54%) · 100% consumerno trial arm names this drug
Synovitis3,82530.2
29.1–31.3ROR 30.8 · calibrated p 2e-4 ✓
23.9 EB05 23.3 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious PRR 17.6 · ♀ 97% (drug 54%) · 93% clinicianno trial arm names this drug
Irritable bowel syndrome4,16827.2
26.3–28.1ROR 27.8 · calibrated p 4e-4 ✓
22.0 EB05 21.4 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious PRR 19.6 · ♀ 99% (drug 54%) · 92% clinicianno trial arm names this drug
Breast cancer stage iii1,24126.8
25.2–28.5ROR 27.0 · calibrated p 5e-4 ✓
21.7 EB05 20.8 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=1,241 · ♀ 100% (drug 54%) · 94% clinicianno trial arm names this drug
Lip dry1,70026.3
24.9–27.7ROR 26.5 · calibrated p 5e-4 ✓
21.4 EB05 20.6 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=1,681 · ♀ 100% (drug 54%) · 94% clinicianno trial arm names this drug
Toxic leukoencephalopathy12523.3
19.2–28.3ROR 23.4 · calibrated p 0.001 ✓
19.4 EB05 16.7 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=125 · ♀ 0% (drug 54%) · 100% clinicianno trial arm names this drug
Drug dependence27,70823.0
22.7–23.3ROR 26.9 · calibrated p 5e-4 ✓
19.2 EB05 19.0 · IC025 +4.2
3/3 methods agree
Reporting / coding artifactage-adj. PRR 8.5 · serious PRR 13.8 · 90% consumerno trial arm names this drug
Catarrh14822.4
18.7–26.7ROR 22.4 · calibrated p 0.001 ✓
18.7 EB05 16.3 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=148 · ♀ 0% (drug 54%) · 100% clinicianno trial arm names this drug
Onychomadesis68222.0
20.3–23.9ROR 22.1 · calibrated p 0.001 ✓
18.5 EB05 17.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=676 · ♀ 100% (drug 54%) · 91% clinicianno trial arm names this drug
Opisthotonus13021.7
18.0–26.2ROR 21.7 · calibrated p 0.001 ✓
18.3 EB05 15.8 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=130no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Dependence / withdrawal30,92713.112.9–13.2signal
Liver injury7,0062.72.6–2.7signal
Suicidality5,3212.52.4–2.5signal
Interstitial lung disease1,8572.22.1–2.3signal
Depression5,4002.22.1–2.2signal
Serious infection13,0761.91.9–2.0raised
Venous thromboembolism2,8741.51.5–1.6raised
Kidney injury5,9101.51.4–1.5raised
Fall / fracture4,9021.51.4–1.5raised
Hyperglycaemia / diabetes4,0301.31.3–1.4raised
Thrombocytopenia2,5531.31.3–1.4raised
Hyponatraemia9301.31.2–1.4raised
Tendon disorder4351.31.2–1.4raised
Rhabdomyolysis / myopathy8861.21.2–1.3raised
Anaemia3,2201.21.2–1.3raised
Gi bleeding1,8761.21.1–1.2raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Oxycodone only as a background or rescue medication (NCT02625181, NCT04296396); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug dependence27,70823.0
22.7–23.3ROR 26.9 · calibrated p 5e-4 ✓
19.2 EB05 19.0 · IC025 +4.2
3/3 methods agree
Reporting / coding artifactage-adj. PRR 8.5 · serious PRR 13.8 · 90% consumerno trial arm names this drug
Pain26,8995.1
5.1–5.2ROR 5.8 · calibrated p 0.163
4.9 EB05 4.9 · IC025 +2.3
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 2.9 · serious PRR 5.0no trial arm names this drug
Death19,8432.6
2.6–2.7ROR 2.8 · calibrated p 0.683
2.6 EB05 2.6 · IC025 +1.4
3/3 methods agree
Outcome field, not a reaction
boxed warning mentions mortality
age-adj. PRR 1.7 · serious PRR 1.8no trial arm names this drug
Overdose19,26210.9
10.8–11.1ROR 12.1 · calibrated p 0.016 ✓
10.0 EB05 9.9 · IC025 +3.3
3/3 methods agree
Reporting / coding artifactage-adj. PRR 3.5 · serious PRR 8.9 · 70% consumerno trial arm names this drug
Toxicity to various agents16,48412.2
12.0–12.4ROR 13.3 · calibrated p 0.011 ✓
11.1 EB05 10.9 · IC025 +3.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 5.7 · serious PRR 8.0no trial arm names this drug
Emotional distress15,68316.6
16.3–16.9ROR 18.0 · calibrated p 0.003 ✓
14.6 EB05 14.4 · IC025 +3.8
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.3 · serious PRR 11.1 · 89% consumerno trial arm names this drug
Fatigue (tiredness)12,3841.8
1.8–1.8ROR 1.9 · calibrated p 0.871
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 2.1 · serious PRR 1.8no trial arm names this drug
Drug ineffective (drug did not work)11,8921.0
1.0–1.0ROR 1.0 · calibrated p 0.320
1.0 EB05 1.0 · IC025 -0.0
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 1.5 · serious PRR 1.4no trial arm names this drug
Nausea11,1471.6
1.6–1.6ROR 1.6 · calibrated p 0.732
1.6 EB05 1.6 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 1.5no trial arm names this drug
Drug withdrawal syndrome10,52215.1
14.8–15.4ROR 15.9 · calibrated p 0.005 ✓
13.4 EB05 13.2 · IC025 +3.7
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 4.1 · serious PRR 11.5no trial arm names this drug
Off label use (used outside approved label)8,7571.1
1.1–1.2ROR 1.1 · calibrated p 0.404
1.1 EB05 1.1 · IC025 +0.2Reporting / coding artifactage-adj. PRR 1.5 · serious PRR 1.2no trial arm names this drug
Diarrhoea (diarrhea)8,6191.5
1.5–1.6ROR 1.5 · calibrated p 0.670
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 1.4no trial arm names this drug
Dyspnoea (shortness of breath)8,0781.6
1.6–1.7ROR 1.6 · calibrated p 0.737
1.6 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 1.4 · ♀ 74% (drug 54%)no trial arm names this drug
Vomiting7,9121.9
1.9–2.0ROR 2.0 · calibrated p 0.922
1.9 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 2.2 · serious PRR 1.7 · ♀ 74% (drug 54%)no trial arm names this drug
Rash7,6862.0
2.0–2.1ROR 2.1 · calibrated p 0.978
2.0 EB05 2.0 · IC025 +1.0Labeled adverse reaction
exact term
age-adj. PRR 2.5 · serious PRR 2.7 · ♀ 82% (drug 54%)no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Oxycodone?

In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone are pain, toxicity to various agents, emotional distress, fatigue, nausea, drug withdrawal syndrome. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Oxycodone have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

Do FAERS signals prove that Oxycodone causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.